Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Phase II study of Dovitinib in recurrent glioblastoma.

Sharma M, Schilero C, Peereboom DM, Hobbs BP, Elson P, Stevens GHJ, McCrae K, Nixon AB, Ahluwalia MS.

J Neurooncol. 2019 Jul 11. doi: 10.1007/s11060-019-03236-6. [Epub ahead of print]

PMID:
31292802
2.

Time to surgery and its impact on survival in patients with endometrial cancer: A National cancer database study.

AlHilli MM, Elson P, Rybicki L, Khorana AA, Rose PG.

Gynecol Oncol. 2019 Jun;153(3):511-516. doi: 10.1016/j.ygyno.2019.03.244. Epub 2019 Apr 15.

PMID:
31000472
3.

A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.

Advani AS, Cooper B, Visconte V, Elson P, Chan R, Carew J, Wei W, Mukherjee S, Gerds A, Carraway H, Nazha A, Hamilton B, Sobecks R, Caimi P, Tomlinson B, Malek E, Little J, Miron A, Pink J, Maciejewski J, Unger A, Kalaycio M, de Lima M, Sekeres MA.

Clin Cancer Res. 2019 Apr 16. doi: 10.1158/1078-0432.CCR-18-3886. [Epub ahead of print]

PMID:
30992301
4.

Correction: Time to initial cancer treatment in the United States and association with survival over time: An observational study.

Khorana AA, Tullio K, Elson P, Pennell NA, Grobmyer SR, Kalady MF, Raymond D, Abraham J, Klein EA, Walsh RM, Monteleone EE, Wei W, Hobbs B, Bolwell BJ.

PLoS One. 2019 Apr 4;14(4):e0215108. doi: 10.1371/journal.pone.0215108. eCollection 2019.

5.

Time to initial cancer treatment in the United States and association with survival over time: An observational study.

Khorana AA, Tullio K, Elson P, Pennell NA, Grobmyer SR, Kalady MF, Raymond D, Abraham J, Klein EA, Walsh RM, Monteleone EE, Wei W, Hobbs B, Bolwell BJ.

PLoS One. 2019 Mar 1;14(3):e0213209. doi: 10.1371/journal.pone.0213209. eCollection 2019. Erratum in: PLoS One. 2019 Apr 4;14(4):e0215108.

6.

Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.

Sharma M, Schroeder JL, Elson P, Meola A, Barnett GH, Vogelbaum MA, Suh JH, Chao ST, Mohammadi AM, Stevens GHJ, Murphy ES, Angelov L.

J Neurosurg. 2018 Oct 1:1-11. doi: 10.3171/2018.4.JNS172909. [Epub ahead of print]

PMID:
30485180
7.

Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.

Khunger M, Patil PD, Khunger A, Li M, Hu B, Rakshit S, Basu A, Pennell N, Stevenson JP, Elson P, Panchabhai TS, Velcheti V.

PLoS One. 2018 Oct 25;13(10):e0197743. doi: 10.1371/journal.pone.0197743. eCollection 2018.

8.

Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.

Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P.

Clin Cancer Res. 2019 Jan 1;25(1):210-221. doi: 10.1158/1078-0432.CCR-18-1278. Epub 2018 Oct 16.

9.

Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.

Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, Garcia JA, Grivas P.

Urol Oncol. 2018 Sep;36(9):405-412. doi: 10.1016/j.urolonc.2018.02.018. Epub 2018 Mar 30. Review.

PMID:
29606341
10.

Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma.

Emamekhoo H, Dhillon P, Gopalakrishnan D, Elson P, Stephenson A, Magi-Galluzzi C, McKenney J, Harper H, Haber GP, Kaouk J, Lee B, Fergany A, Berglund R, Gong M, Stein R, Krishnamurthi V, Gilligan T, Ornstein M, Rini B, Garcia J, Grivas P.

Clin Genitourin Cancer. 2018 Aug;16(4):e751-e760. doi: 10.1016/j.clgc.2018.01.014. Epub 2018 Feb 6.

PMID:
29551583
11.

Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors.

Mittal K, Derosa L, Albiges L, Wood L, Elson P, Gilligan T, Garcia J, Dreicer R, Escudier B, Rini B.

Clin Genitourin Cancer. 2018 Jun;16(3):e663-e667. doi: 10.1016/j.clgc.2017.12.014. Epub 2018 Jan 4.

PMID:
29428404
12.

Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer.

Zahoor H, Elson P, Stephenson A, Haber GP, Kaouk J, Fergany A, Lee B, Koshkin V, Ornstein M, Gilligan T, Garcia JA, Rini B, Grivas P.

Clin Genitourin Cancer. 2018 Apr;16(2):e437-e442. doi: 10.1016/j.clgc.2017.10.005. Epub 2017 Oct 17.

PMID:
29154041
13.

Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.

Angelov L, Mohammadi AM, Bennett EE, Abbassy M, Elson P, Chao ST, Montgomery JS, Habboub G, Vogelbaum MA, Suh JH, Murphy ES, Ahluwalia MS, Nagel SJ, Barnett GH.

J Neurosurg. 2018 Aug;129(2):366-382. doi: 10.3171/2017.3.JNS162532. Epub 2017 Sep 22.

PMID:
28937324
14.

Spindle Cell Lipomas in Women: A Report of 53 Cases.

Ko JS, Daniels B, Emanuel PO, Elson P, Khachaturov V, McKenney JK, Goldblum JR, Billings SD.

Am J Surg Pathol. 2017 Sep;41(9):1267-1274. doi: 10.1097/PAS.0000000000000915.

PMID:
28719462
15.

Evaluation of Prognostic Factors for Early Mortality After Stereotactic Radiosurgery for Brain Metastases: a Single Institutional Retrospective Review.

Bennett EE, Vogelbaum MA, Barnett GH, Angelov L, Chao S, Murphy E, Yu J, Suh JH, Elson P, Stevens GHJ, Mohammadi AM.

Neurosurgery. 2018 Jul 1;83(1):128-136. doi: 10.1093/neuros/nyx346.

PMID:
28673040
16.

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.

Kozuki T, Chikamori K, Surleac MD, Micluta MA, Petrescu AJ, Norris EJ, Elson P, Hoeltge GA, Grabowski DR, Porter ACG, Ganapathi RN, Ganapathi MK.

Nucleic Acids Res. 2017 Jun 2;45(10):5995-6010. doi: 10.1093/nar/gkx325.

17.

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.

Sidana S, Narkhede M, Elson P, Hastings D, Faiman B, Valent J, Samaras C, Hamilton K, Liu HK, Smith MR, Reu FJ.

PLoS One. 2017 Mar 9;12(3):e0172996. doi: 10.1371/journal.pone.0172996. eCollection 2017.

18.

A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.

Ornstein MC, Wood LS, Elson P, Allman KD, Beach J, Martin A, Zanick BR, Grivas P, Gilligan T, Garcia JA, Rini BI.

J Clin Oncol. 2017 Jun 1;35(16):1764-1769. doi: 10.1200/JCO.2016.71.1184. Epub 2017 Jan 23.

PMID:
28113029
19.

Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase.

Sahu D, Gupta S, Hau AM, Nakashima K, Leivo MZ, Searles SC, Elson P, Bomalaski JS, Casteel DE, Boss GR, Hansel DE.

Am J Pathol. 2017 Jan;187(1):200-213. doi: 10.1016/j.ajpath.2016.09.004. Epub 2016 Dec 9.

20.

Longitudinal experience with WHO Grade III (anaplastic) meningiomas at a single institution.

Balasubramanian SK, Sharma M, Silva D, Karivedu V, Schmitt P, Stevens GH, Barnett GH, Prayson RA, Elson P, Suh JH, Murphy ES, Chao ST.

J Neurooncol. 2017 Feb;131(3):555-563. doi: 10.1007/s11060-016-2321-8. Epub 2016 Nov 18.

PMID:
27864703
21.

Significance of epidermal mitoses in challenging melanocytic proliferations.

Minca EC, Billings SD, Elson P, Tetzlaff MT, Andea AA, Ko JS.

J Cutan Pathol. 2017 Feb;44(2):135-143. doi: 10.1111/cup.12855. Epub 2016 Dec 15.

22.

Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma.

Ornstein MC, Wood L, Elson P, Allman K, Beach J, Martin A, Gilligan T, Garcia JA, Rini BI.

Clin Genitourin Cancer. 2017 Apr;15(2):e275-e280. doi: 10.1016/j.clgc.2016.08.014. Epub 2016 Aug 18.

PMID:
27625016
23.

A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.

Leivo MZ, Elson PJ, Tacha DE, Delahunt B, Hansel DE.

Pathology. 2016 Oct;48(6):543-9. doi: 10.1016/j.pathol.2016.05.008. Epub 2016 Sep 2.

24.

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.

Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, Garcia JA, Plimack ER.

Lancet Oncol. 2016 Sep;17(9):1317-24. doi: 10.1016/S1470-2045(16)30196-6. Epub 2016 Aug 3.

PMID:
27498080
25.

Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition.

Sanfrancesco J, McKenney JK, Leivo MZ, Gupta S, Elson P, Hansel DE.

Arch Pathol Lab Med. 2016 Jun;140(6):543-51. doi: 10.5858/arpa.2015-0085-OA. Epub 2016 Mar 31.

PMID:
27031776
26.

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.

Chittoria N, Haddad H, Elson P, Tannir NM, Wood LS, Dreicer R, Garcia JA, Rini BI, Jonasch E.

BMC Cancer. 2016 Mar 29;16:254. doi: 10.1186/s12885-016-2282-5.

27.

Transforming Growth Factor-β Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion.

Gupta S, Hau AM, Al-Ahmadie HA, Harwalkar J, Shoskes AC, Elson P, Beach JR, Hussey GS, Schiemann WP, Egelhoff TT, Howe PH, Hansel DE.

Am J Pathol. 2016 May;186(5):1351-60. doi: 10.1016/j.ajpath.2016.01.008. Epub 2016 Mar 14.

28.

Lung cancer treatment outcomes in recipients of lung transplant.

Du L, Pennell NA, Elson P, Hashemi-Sadraei N.

Transl Lung Cancer Res. 2015 Dec;4(6):784-91. doi: 10.3978/j.issn.2218-6751.2015.12.08.

29.

Prospective Clinical Study of Precision Oncology in Solid Tumors.

Sohal DP, Rini BI, Khorana AA, Dreicer R, Abraham J, Procop GW, Saunthararajah Y, Pennell NA, Stevenson JP, Pelley R, Estfan B, Shepard D, Funchain P, Elson P, Adelstein DJ, Bolwell BJ.

J Natl Cancer Inst. 2015 Nov 9;108(3). pii: djv332. doi: 10.1093/jnci/djv332.

PMID:
26553780
30.

Quantitative Evaluation of Local Control and Wound Healing Following Surgery and Stereotactic Spine Radiosurgery for Spine Tumors.

Harel R, Emch T, Chao S, Elson P, Krishnaney A, Djemil T, Suh J, Angelov L.

World Neurosurg. 2016 Mar;87:48-54. doi: 10.1016/j.wneu.2015.10.075. Epub 2015 Nov 5.

PMID:
26548834
31.

Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients.

Ko JS, Prieto VG, Elson PJ, Vilain RE, Pulitzer MP, Scolyer RA, Reynolds JP, Piliang MP, Ernstoff MS, Gastman BR, Billings SD.

Mod Pathol. 2016 Feb;29(2):122-30. doi: 10.1038/modpathol.2015.109. Epub 2015 Nov 6.

32.

Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases.

Ahluwalia MS, Chao ST, Parsons MW, Suh JH, Wang D, Mikkelsen T, Brewer CJ, Smolenski KN, Schilero C, Rump M, Elson P, Angelov L, Barnett GH, Vogelbaum MA, Weil RJ, Peereboom DM.

J Neurooncol. 2015 Sep;124(3):485-91. doi: 10.1007/s11060-015-1862-6. Epub 2015 Aug 6.

PMID:
26245136
33.

Reducing Time to Antibiotic Administration for Febrile Neutropenia in the Emergency Department.

Keng MK, Thallner EA, Elson P, Ajon C, Sekeres J, Wenzell CM, Seastone DJ, Gallagher EM, Weber CM, Earl MA, Mukherjee S, Pohlman B, Cober E, Foster VB, Yuhas J, Kalaycio ME, Bolwell BJ, Sekeres MA.

J Oncol Pract. 2015 Nov;11(6):450-5. doi: 10.1200/JOP.2014.002733. Epub 2015 Jul 28.

PMID:
26220930
34.

A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.

Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, Campbell S, Elson P, Koscielny S, Lopatin M, Svedman C, Martini JF, Williams JA, Verkarre V, Radulescu C, Neuzillet Y, Hemmerlé I, Timsit MO, Tsiatis AC, Bonham M, Lebret T, Mejean A, Escudier B.

Lancet Oncol. 2015 Jun;16(6):676-85. doi: 10.1016/S1470-2045(15)70167-1. Epub 2015 May 12.

PMID:
25979595
35.

Enhanced IMP3 Expression Activates NF-кB Pathway and Promotes Renal Cell Carcinoma Progression.

Pei X, Li M, Zhan J, Yu Y, Wei X, Guan L, Aydin H, Elson P, Zhou M, He H, Zhang H.

PLoS One. 2015 Apr 28;10(4):e0124338. doi: 10.1371/journal.pone.0124338. eCollection 2015.

36.

A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma.

Rini BI, Plimack ER, Takagi T, Elson P, Wood LS, Dreicer R, Gilligan T, Garcia J, Zhang Z, Kaouk J, Krishnamurthi V, Stephenson AJ, Fergany A, Klein EA, Uzzo RG, Chen DY, Campbell SC.

J Urol. 2015 Aug;194(2):297-303. doi: 10.1016/j.juro.2015.03.096. Epub 2015 Mar 23.

PMID:
25813447
37.

Tumor progression in patients receiving adjuvant whole-brain radiotherapy vs localized radiotherapy after surgical resection of brain metastases.

Hsieh J, Elson P, Otvos B, Rose J, Loftus C, Rahmathulla G, Angelov L, Barnett GH, Weil RJ, Vogelbaum MA.

Neurosurgery. 2015 Apr;76(4):411-20. doi: 10.1227/NEU.0000000000000626.

PMID:
25599198
38.

Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy.

Ornstein MC, Mukherjee S, Keng M, Elson P, Tiu RV, Saunthararajah Y, Maggiotto A, Schaub M, Banks D, Advani A, Kalaycio M, Maciejewski JP, Sekeres MA.

Leuk Lymphoma. 2015;56(9):2536-42. doi: 10.3109/10428194.2014.1003557. Epub 2015 Feb 20.

PMID:
25563427
39.

Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.

Ahluwalia MS, Xie H, Dahiya S, Hashemi-Sadraei N, Schiff D, Fisher PG, Chamberlain MC, Pannullo S, Newton HB, Brewer C, Wood L, Prayson R, Elson P, Peereboom DM.

J Neurooncol. 2015 Mar;122(1):111-9. doi: 10.1007/s11060-014-1684-y. Epub 2014 Dec 23.

PMID:
25534576
40.

Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer.

Chaturvedi S, Sidana S, Elson P, Khorana AA, McCrae KR.

PLoS One. 2014 Aug 15;9(8):e94048. doi: 10.1371/journal.pone.0094048. eCollection 2014.

41.

Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.

Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, Borden EC, Rini BI.

Cancer Biol Ther. 2014 Aug;15(8):975-81. doi: 10.4161/cbt.29187. Epub 2014 May 19.

42.

Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma.

Joshi P, Jacobs B, Derakhshan A, Moore LR, Elson P, Triozzi PL, Borden E, Zborowski M.

Oncotarget. 2014 May 15;5(9):2450-61.

43.

The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study.

Mohammadi AM, Hawasli AH, Rodriguez A, Schroeder JL, Laxton AW, Elson P, Tatter SB, Barnett GH, Leuthardt EC.

Cancer Med. 2014 Aug;3(4):971-9. doi: 10.1002/cam4.266. Epub 2014 May 9.

44.

Clinical and Radiographic Outcomes From Repeat Whole-brain Radiation Therapy for Brain Metastases in the Age of Stereotactic Radiosurgery.

Guo S, Balagamwala EH, Reddy C, Elson P, Suh JH, Chao ST.

Am J Clin Oncol. 2016 Jun;39(3):288-93. doi: 10.1097/COC.0000000000000051.

PMID:
24608225
45.

Phase II trial of patupilone in patients with brain metastases from breast cancer.

Peereboom DM, Murphy C, Ahluwalia MS, Conlin A, Eichler A, Van Poznak C, Baar J, Elson P, Seidman AD.

Neuro Oncol. 2014 Apr;16(4):579-83. doi: 10.1093/neuonc/not305. Epub 2014 Jan 26.

46.

Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.

Salem ME, Shah SN, Elson P, Garcia JA, Wood LS, Medsinge A, Campbell S, Dreicer R, Rini BI.

Clin Genitourin Cancer. 2014 Apr;12(2):117-23. doi: 10.1016/j.clgc.2013.08.001. Epub 2013 Oct 12.

PMID:
24126239
47.

Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia.

Ornstein MC, Mukherjee S, Mohan S, Elson P, Tiu RV, Saunthararajah Y, Kendeigh C, Advani A, Kalaycio M, Maciejewski JP, Sekeres MA.

Am J Hematol. 2014 Feb;89(2):168-73. doi: 10.1002/ajh.23605. Epub 2013 Nov 21.

48.

Surgical outcomes of trigeminal neuralgia in patients with multiple sclerosis.

Mohammad-Mohammadi A, Recinos PF, Lee JH, Elson P, Barnett GH.

Neurosurgery. 2013 Dec;73(6):941-50; discussion 950. doi: 10.1227/NEU.0000000000000128.

PMID:
23921703
49.

Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.

Garcia JA, Elson P, Tyler A, Triozzi P, Dreicer R.

Urol Oncol. 2014 Jan;32(1):33.e11-7. doi: 10.1016/j.urolonc.2012.12.004. Epub 2013 Mar 17.

PMID:
23510862
50.

Role of Gamma Knife surgery in patients with 5 or more brain metastases.

Mohammadi AM, Recinos PF, Barnett GH, Weil RJ, Vogelbaum MA, Chao ST, Suh JH, Marko NF, Elson P, Neyman G, Angelov L.

J Neurosurg. 2012 Dec;117 Suppl:5-12. doi: 10.3171/2012.8.GKS12983.

PMID:
23205782

Supplemental Content

Loading ...
Support Center